| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J Thorac Cardiovasc Surg 1994;108:329-336
© 1994 Mosby, Inc.
GENERAL THORACIC SURGERY |
Isehara, Kanagawa, Japan
From the First Department of Surgery, Tokai University, School of Medicine, Bohseidai, Isehara, Kanagawa, 259-11, Japan.
Received for publication Oct. 8, 1993. Accepted for publication Jan. 9, 1994. Address for reprints: Jun-ichi Ogawa, M.D. First Department of Surgery, Tokai University, School of Medicine, Bohseidai, Isehara, Kanagawa, 259-11, Japan.
Abstract
Blood vessel invasion, recurrence rate, and time to recurrence were examined in relation to the immunohistochemical expression of proliferating cell nuclear antigen, sialyl Lewis X, andsialyl Lewis ain 303 patients with lung cancer who had a curative resection from 1980 to 1991. Of these, 150 had adenocarcinoma, 117 had squamous, 21 had large-cell, and 15 had small-cell carcinoma. Significant differences were detected in the expression of proliferating cell nuclear antigen and sialyl Lewis Xbetween adenocarcinomas and the other histologic types; thus the subjects were divided into 150 with adenocarcinoma and 153 with non-adenocarcinoma. In those with adenocarcinoma, the frequency of blood vessel invasion was significantly higher in tumors with strong sialyl LewisXexpression, and the disease-free survival of the patients with blood vessel invasion was significantly worse when their tumors strongly expressed both sialyl LewisXand proliferating cell nuclear antigen. In those with non-adenocarcinoma, on the other hand, tumors with strong expression of sialyl Lewisaand proliferating cell nuclear antigen showed significantly higher frequencies of blood vessel invasion and worse disease-free survival. In patients with recurrent tumors, those with strong proliferating cell nuclear antigen expression showed a significantly shorter time to recurrence. We conclude that sialyl LewisXand proliferating cell nuclear antigen expression inadenocarcinoma and sialyl Lewisaand proliferating cell nuclear antigen expression in non-adenocarcinoma may be an important determinant of recurrence. (J THORACCARDIOVASCSURG1994;108:329-36)
This article has been cited by other articles:
|
|
 |
|
  S. Mathieu, M. Prorok, A.-M. Benoliel, R. Uch, C. Langlet, P. Bongrand, R. Gerolami, and A. El-Battari Transgene Expression of {alpha}(1,2)-Fucosyltransferase-I (FUT1) in Tumor Cells Selectively Inhibits Sialyl-Lewis x Expression and Binding to E-Selectin without Affecting Synthesis of Sialyl-Lewis a or Binding to P-Selectin Am. J. Pathol., February 1, 2004; 164(2): 371 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Fuster, J. R. Brown, L. Wang, and J. D. Esko A Disaccharide Precursor of Sialyl Lewis X Inhibits Metastatic Potential of Tumor Cells Cancer Res., June 1, 2003; 63(11): 2775 - 2781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E.V. Chandrasekaran, R. Chawda, J. M. Rhodes, J. Xia, C. Piskorz, and K. L. Matta Human lung adenocarcinoma {{alpha}}1,3/4-L-fucosyltransferase displays two molecular forms, high substrate affinity for clustered sialyl LacNAc type 1 units as well as mucin core 2 sialyl LacNAc type 2 unit and novel {{alpha}}1,2-L-fucosylating activity Glycobiology, May 1, 2001; 11(5): 353 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Machida, J. Nakayama, J. Amano, and M. Fukuda Clinicopathological Significance of Core 2 {beta}1,6-N-Acetylglucosaminyltransferase Messenger RNA Expressed in the Pulmonary Adenocarcinoma Determined by in Situ Hybridization Cancer Res., March 1, 2001; 61(5): 2226 - 2231. [Abstract] [Full Text]
|
|
|
|
 |
|
 Corrigenda for vol. 155, p. 1419 Am. J. Respir. Crit. Care Med., July 1, 1997; 156(2): 677 - 678. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
